NIH-funded research NIH-funded research

MATCHMAKERS: AI tools to predict TCR binding and design

Official title: MATCHMAKERS - Creating and training AI tools for TCR binding prediction and design

Funded at Massachusetts Institute of Technology · NIH-11514453 · Data updated 2026-11-12

Researchers are building AI tools to predict how T cell receptors recognize tumor antigens, with aims to help improve targeted immunotherapies.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionMassachusetts Institute of Technology
NIH-funded
Lab location1 site (Cambridge, United States)
Project startMay 1, 2024
Project endApril 30, 2027
Funding year2026
Award (this year)$1,209,684
NIH project number3OT2CA297463-01S2
Project IDNIH-11514453 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates are patients with cancer or immune-related conditions whose tumor antigens could be targeted by TCR-based therapies.

Less likely to help

Patients not eligible for TCR-targeted therapies or without tumor antigens suitable for TCR recognition may see limited direct benefit.

What this research studies

This grant brings together immunology, structural biology, and computational experts to create large datasets of TCR-pMHC pairs and develop ultra-fast AI methods to predict recognition. The work is designed to generate generalized models that can guide design of TCRs and their targets, using human and mouse data from cancer and immunity contexts. By combining sequencing, structural insights, and machine learning, the team hopes to accelerate understanding of TCR-antigen interactions relevant to cancer therapy. The project is organized into four work packages focusing on data generation, high-throughput matching, model development, and validation.

Why it matters

Potential benefit: If successful, patients could see faster development of personalized or more effective T cell-based immunotherapies.

How similar studies have gone: Preliminary work in TCR-antigen prediction and high-throughput data generation has shown promise, but robust generalized predictors remain an area of active development.

Where this research is happening

  • Massachusetts Institute of Technology
    Cambridge, United States
    Active

Researchers

  • Principal investigator: Birnbaum, Michael — Massachusetts Institute of Technology
  • Study coordinator: Birnbaum, Michael

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.